These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31923471)

  • 1. Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.
    Galindo-Mendez B; Trevino JA; McGlinchey R; Fortier C; Lioutas V; Novak P; Mantzoros CS; Ngo L; Novak V
    Contemp Clin Trials; 2020 Feb; 89():105934. PubMed ID: 31923471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
    Novak V; Mantzoros CS; Novak P; McGlinchey R; Dai W; Lioutas V; Buss S; Fortier CB; Khan F; Aponte Becerra L; Ngo LH
    J Neurol; 2022 Sep; 269(9):4817-4835. PubMed ID: 35482079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes.
    Novak V; Milberg W; Hao Y; Munshi M; Novak P; Galica A; Manor B; Roberson P; Craft S; Abduljalil A
    Diabetes Care; 2014; 37(3):751-9. PubMed ID: 24101698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes.
    Zhang H; Hao Y; Manor B; Novak P; Milberg W; Zhang J; Fang J; Novak V
    Diabetes; 2015 Mar; 64(3):1025-34. PubMed ID: 25249577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Apr; 218():111898. PubMed ID: 38159613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
    JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2023 Jul; 213():111825. PubMed ID: 37245533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up.
    Becerra LA; Gavrieli A; Khan F; Novak P; Lioutas V; Ngo LH; Novak V; Mantzoros CS
    Clin Nutr; 2023 Jun; 42(6):825-834. PubMed ID: 37084469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of 40 and 80 units of insulin does not cause hypoglycemia during cardiac surgery: a randomized controlled trial.
    Roque P; Nakadate Y; Sato H; Sato T; Wykes L; Kawakami A; Yokomichi H; Matsukawa T; Schricker T
    Can J Anaesth; 2021 Jul; 68(7):991-999. PubMed ID: 33721199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
    Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
    J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
    Aponte Becerra L; Galindo Mendez B; Khan F; Lioutas V; Novak P; Mantzoros CS; Ngo LH; Novak V
    Arch Diabetes Obes; 2022; 4(2):403-415. PubMed ID: 35903156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder.
    Cha DS; Best MW; Bowie CR; Gallaugher LA; Woldeyohannes HO; Soczynska JK; Lewis G; MacQueen G; Sahakian BJ; Kennedy SH; Lui JP; Mansur RB; McIntyre RS
    J Affect Disord; 2017 Mar; 210():57-65. PubMed ID: 28013123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
    Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
    Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
    Reger MA; Watson GS; Green PS; Baker LD; Cholerton B; Fishel MA; Plymate SR; Cherrier MM; Schellenberg GD; Frey WH; Craft S
    J Alzheimers Dis; 2008 Apr; 13(3):323-31. PubMed ID: 18430999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
    Kellar D; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
    J Prev Alzheimers Dis; 2021; 8(3):240-248. PubMed ID: 34101779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dropout risk and effectiveness of retention strategies in the Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Clinical Trial.
    Isaza-Pierrotti DF; Khan F; Novak P; Lioutas V; Mantzoros CS; Ngo LH; Novak V
    Contemp Clin Trials; 2023 Feb; 125():107057. PubMed ID: 36539060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.
    Samaras K; Makkar S; Crawford JD; Kochan NA; Wen W; Draper B; Trollor JN; Brodaty H; Sachdev PS
    Diabetes Care; 2020 Nov; 43(11):2691-2701. PubMed ID: 32967921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.